Penn Pharma, a PCI company, has over 35 years of experience in providing integrated drug development, clinical trial supply, manufacturing and packaging services to the international healthcare industry. With a full range of contract services available Penn is able to take compounds from the earliest stages of development through to commercialisation. It is this “molecule to market” offering from Penn that ensures true speed to market for our global client base. Recognised for our regulatory and export experience, Penn supplies many markets including Europe, the USA, South America and Japan. Our Knowledge and expertise, has enabled us to become the trusted partner for many of the world’s top pharmaceutical companies. In recent years, we have invested to expand our operations including a purpose-built contained manufacturing facility which opened in 2013 followed by a large-scale commercial manufacturing suite which became operational in 2014. With this significant expansion programme, we are now able to offer over 0.5 billion doses of capacity on site ranging from 1kg to 300kg scale for non-potent and 1kg to 120kg scale for potent molecules. Penn's facilities meet the highest quality and regulatory standards, are licensed by the MHRA and inspected by the FDA. Penn is also licensed by the UK Home Office for importation and storage of controlled drugs. Core services include: Formulation development, Analytical development & stability, Clinical trial supply, Manufacturing - Clinical/Commercial/Contained, including highly potent molecules, from pilot to commercial batch sizes, Manufacture of specials (unlicensed medicines), Supply chain management - including the storage, distribution, returns, destruction and inventory management of clinical trial material, QA services, Qualified Person (QP) Release. Dosage forms include; Solid - tablets, capsules, granules, powders, Semi solid - creams, ointment & gels, Liquids - solutions & suspensions.